‘Skinny Label’ Case Gives Brands A ‘Blueprint’ To Alter Use Codes In Patent Litigation

Implications Of GSK v. Teva 'Scarier For Biosimilars'

Federal Circuit ruling in GSK v. Teva shows brands can broaden a use code to include other patented indications years into litigation, AAM attorney says. The case is ‘scarier’ for biosimilar makers since they must market their products, Teva lawyer notes.

carve-out
Label-carve out case raises concerns about biosimilar litigation and marketing • Source: Alamy

More from Legal & IP

More from Generics Bulletin